Literature DB >> 17380298

Genetic changes in bilateral breast cancer by comparative genomic hybridisation.

S-C Park1, U-K Hwang, S-H Ahn, G-Y Gong, H-S Yoon.   

Abstract

The aim of this study is to find any specific genetic defect occurring frequently in bilateral breast cancer by examining the genetic changes of each chromosome using comparative genomic hybridisation (CGH). CGH was conducted for 36 breast cancer tissues taken from patients treated with surgery for bilateral breast cancer. Tumour and control DNAs were hybridised to metaphase chromosome with differential staining with fluorescein and rhodamine-dUTP. An average rate of green (DNA of tumour cell) against red (DNA of a normal peripheral blood lymphocyte) was calculated in these captured metaphase chromosomes and a ratio of more than 1.17 was defined as an acquisition, less than 0.85 as a loss and, finally, more than 2 as amplification. Twenty-six out of 36 cases (72.2%) showed a change in the number of DNA copies by CGH in one or more regions of gene. On average, 5.3 alterations for each chromosome (range, 1-14) were found, and gain was present more than loss at a ratio of 1.3:1. Loci that showed amplification were X, 17q, Xq, 8q, 14q11-21 and 17q22-qter. The locus showing the most gain was the X chromosome, which was observed in 15 (57.7%) out of 26 cases. Loss was most frequently observed in the short arm of chromosome 8. The concordance of genetic transformation of primary cancer and secondary cancer in bilateral breast cancer was an average of 18.7% in synchronous and 10.7% in metachronous cancer, showing higher similarity in synchronous breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17380298     DOI: 10.1007/s10238-007-0123-1

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  7 in total

1.  Testing clonal relatedness of tumors using array comparative genomic hybridization: a statistical challenge.

Authors:  Irina Ostrovnaya; Colin B Begg
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data.

Authors:  Irina Ostrovnaya; Adam B Olshen; Venkatraman E Seshan; Irene Orlow; Donna G Albertson; Colin B Begg
Journal:  Stat Med       Date:  2010-07-10       Impact factor: 2.373

3.  Histo-biological comparative analysis of bilateral breast cancer.

Authors:  Bilal Baker; Basem Morcos; Faiez Daoud; Maher Sughayer; Maher Sughayyer; Hisham Shabani; Habeeb Salameh; Mahmoud Almasri
Journal:  Med Oncol       Date:  2013-09-24       Impact factor: 3.064

4.  Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers.

Authors:  Nicolas Girard; Irina Ostrovnaya; Christopher Lau; Bernard Park; Marc Ladanyi; David Finley; Charuhas Deshpande; Valerie Rusch; Irene Orlow; William D Travis; William Pao; Colin B Begg
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

5.  Comparative genomic analysis reveals bilateral breast cancers are genetically independent.

Authors:  Fangfang Song; Xiangchun Li; Fengju Song; Yanrui Zhao; Haixin Li; Hong Zheng; Zhibo Gao; Jun Wang; Wei Zhang; Kexin Chen
Journal:  Oncotarget       Date:  2015-10-13

6.  Clonal relatedness in tumour pairs of breast cancer patients.

Authors:  Jana Biermann; Toshima Z Parris; Szilárd Nemes; Anna Danielsson; Hanna Engqvist; Elisabeth Werner Rönnerman; Eva Forssell-Aronsson; Anikó Kovács; Per Karlsson; Khalil Helou
Journal:  Breast Cancer Res       Date:  2018-08-09       Impact factor: 6.466

7.  Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition.

Authors:  Muthulakshmi Muthuswami; Vignesh Ramesh; Saikat Banerjee; Soundara Viveka Thangaraj; Jayaprakash Periasamy; Divya Bhaskar Rao; Georgina D Barnabas; Swetha Raghavan; Kumaresan Ganesan
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.